Background: Hepatitis B (HBV)-associated end-stage liver disease used to be a rele-
reinfection-rate was almost 100% and a two-year graft and patient survival at approximately 50%. [5] [6] [7] Reasons were the enhanced virus replication resulting from immunosuppression and the lack of adequate treatment options. 4, 8 The administration of HBV-immunoglobulin (HBIG), a polyclonal antibody to HBV surface antigen (HBsAg), and the development of antiviral drugs such as nucleoside analogues (lamivudine and famciclovir), nucleotide analogues adefovir and later entecavir or tenofovir significantly changed survival and outcome. 4, 9, 10 During the last three decades, different strategies were developed to prevent HBV-reinfection, ranging from a single application of HBIG to combinations of modern nucleoside/nucleotide analogues (NUCs)
with HBIG as well as HBIG-free regimen after HBIG-discontinuation.
The single use of HBIG even with anti-HBs-titers over 500 U/L bares the risk of HBV-recurrence in up to 60% as HBV develops escape variants. [11] [12] [13] NUCs suppress the replication of HBV by preventing the synthesis of reverse transcriptase and control the progression of the disease. 7 A combined therapy raised survival rates over 75%
and decreased HBV-recurrence to less than 10% after 5 years.
7, [14] [15] [16] However, drug resistance may reduce long-term effectiveness. 3 HBV has a DNA genome, but it replicates through reverse transcription of an RNA-intermediate, which may result in mutations at multiple nucleotide positions in the genome. 7, 17, 18 HBV-recurrence after LT used to be a serious issue and may be associated with allograft dysfunction, development of fibrosis and cirrhosis of the graft and with graft failure as major complications. 13, 19, 20 Prevention of HBV-reinfection is the major goal and the antiviral resistance of NUCs may be a common problem for such patients because of the long-term use.
14,21
Therefore, the optimization of use, type, duration and dose of antiviral treatment before and after LT is important. The aim of the present analysis was to compare different strategies of HBV-prophylaxis, the rate and the severity of HBV-recurrence especially at the histological level,to sum up the results of 30 years at a high-volume transplant center and to adapt the relevance of HBV-recurrence to modern times.
| PATIENTS AND ME THODS
352 patients underwent 372 liver transplantations at our clinic due HBV-induced end-stage liver disease from 1988 until today. All patients received 10.000 units of HBIG (Hepatect®) in the anhepatic phase followed by different modes of long-term HBV-reinfection prophylaxis. That ranges from no prophylaxis at all to dual prophylaxis with intravenous HBIG application to achieve anti-Hbstiters more than 100 U/mL and an oral NUC: long-term monotherapy with HBIG (HBIG mono), combined therapy of HBIG and lamivudine (HBIG + LAM) and dual prophylaxis with HBIG and entecavir or tenofovir (ETV or TDF) as well as a successful vaccination.
If HBV-reinfection occurred, the administration of HBIG was stopped while keeping the NUC and changing the NUC to a more potent one. HBV-reinfection was defined as a detection of HBs-
Ag or HBV-DNA 1 month after a maximum of preventive measures posttransplant and the incidence was determined in the entire co- 1988-1995; 1996-2005; 2006-2017) were buildt according to the year of transplantation and the dominant mode of HBV-prophylaxis.
In the first period, (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) and with high genetic barrier to resistance NUC (ETV, TDF) in 22 (6.3%) patients. In 15 (4.3%) patients, a post-transplant vaccination was successful, so that HBIG-application and NUC were stopped.
Demographic data of the total cohort are displayed in Table 1 .
HBV-reinfection was detected in 101 (28.7%) cases of the first trans- Table 2 .
| Serology
At the moment of LT all patients were anti-Hbc-positive, 74% of patients showed a positive Hbs-Ag and the remaining 26% were negative for Hbs-Ag and HBV-DNA. HBV-reinfection rate was significantly higher compared to patients with a negative Hbs-Ag (33.8% vs 10.0%, P < 0.001). Hbe-Ag-positive patients demonstrated a significantly higher HBV-reinfection rate than Hbe-Ag-negative patients (56.8% vs 21.9%; P < 0.001). Analogously, anti-Hbe-positive patients experienced HBV-reinfection significantly less frequently than anti-Hbe-negative patients (22.5% vs 47.7%; P = 0.001) as displayed in Table 2 . The majority of Hbs-Ag-negative patients were negative for Hbe-Ag (96.2%) and positive for anti-Hbe (77.8%) because of partial seroconversion.
| Mode of HBV-prophylaxis.
Twelve patients did not receive any HBV-prophylaxis apart from intra- HBV-reinfection prophylaxis on the first postoperative day to the intravenous HBIG thus significantly lowering the reinfection rate to 24.0%.
Since the introduction of more potent NUCs such as entecavir and tenofovir, the HBV-reinfection actually stopped to be an issue after LT at all.
The reinfection rate sank to 0% as displayed in Table 2 and Figure 1 .
Patients receiving any NUC and HBIG developed significantly less fre- 
| Survival
Patients with HBV-reinfection demonstrated a significantly poorer survival than patients without reinfection (log rank; P = 0.004) regard- 
| Mortui vivos docent

| Histology
Histological results were available in 151 patients as part of protocol (Table 3) . 
| Hbs-Ag-clearance after reinfection
| D ISCUSS I ON
The data were obtained on clinical, laboratory and especially histological level in a homogenous, maximally characterized patient cohort from a large volume European liver transplant center. The aim of the study was to sum up the results of a 30 year LT program and to adapt new findings on the subject of HBV-reinfection to the current knowledge. Fortunately, the incidence of an uncontrolled HBV-reinfection has significantly declined in the past two decades. HBV-reinfection is defined as the serological reappearance of HBs-Ag, often accompanied by a high load of HBV-DNA and a positive result for
HBe-Ag in LT-patients with a prevalence ranges up to 80%-100% without prophylaxis. 19, 21 According to the present analysis, HBVreinfection is not as severe as it used to be before the mid 90ies LT. 26 The most important issue is the advent of effective NUC-based prophylaxis, so that the impact of immunosuppression including corticosteroids is less dominant as it used to be. In our cohort, all patients received corticosteroids according to a standard regimen with six weeks. Uncontrolled HBV-recurrence has become a very rare phenomenon due to highly effective NUCs with high genetic barrier to resistance.
The extent of HBV-recurrence has dramatically improved no more being as severe as it used to be until the early nineties and the term "HBV-reinfection" is not equivalent to HBV-recurrence anymore and does not implicate severe graft damage if recognized on time. Therefore, the number of liver related deaths mainly from an uncontrolled HBV-reinfection declined gradually according to our analysis.
Patients with HBV-reinfection showed significantly poorer overall survival compared to those without. Primary graft failure and HBV-associated graft loss were significantly associated with HBV-recurrence especially in the 80ies and early 90ies. The appearance of cholestatic hepatitis as described in the early 90ies actually does not happen anymore because HBV-reinfection can easily be controlled with modern NUCs if diagnosed on time.
The so-called high-risk patients for HBV-recurrence include those with HBV-induced cirrhosis, a positive HBs-Ag and high viral load of HBV-DNA at the time of transplantation and antiviral drug-resistance 19, 20, 28 . Lower risk is attributed to patients with HBV-related acute liver failure, HDV-coinfection and cirrhotic patients with negative HBe-Ag and low HBV-DNA serum levels at the time of transplantation. 19, 20, 28 In contrast to former studies, we did not identify a significantly higher risk for patients with HBV-induced cirrhosis. Positive HBs-Ag and
Hbe-Ag were also significantly predictive for HBV-recurrence, along
Survival depending on Hbs-Ag-clearance after HBV-reinfection. Log-rank-test
Overall survival depending on HBs-Agclearance after HBV-reinfection compared with non-reinfected population. Log-ranktest with negative Anti-HBe and a lower titer for Anti-Hbs. We could not prove HDV-coinfection but HCV-coinfection as a phenomenon with a lower risk for HBV-reinfection. HCV-coinfection may interact and suppress HBV-replication, since HBV-reactivation had been reported after successful treatment of HCV. 29 In the multivariate analysis, the impact disappeared. or less of therapy, followed by a switch to an oral regimen of one or two NUCs seemed to be effective to prevent HBV-recurrence. 22, 31, 33, 34, 36 We weaned 67 patients from HBIG and only 1 patient developed a positive Hbs-Ag that became negative in the next laboratory control (1.5%). Fung et al reported about a recurrence rate of 22.5% among patients receiving entecavir as prophylaxis after HBIG discontinuation (n = 80). 31 Wahawan et al used single or double antiviral treatment and achieved 8% recurrence rate (n = 75). 38 HBIG is definitely effective, however it may mask HBV-replication if an inadequate NUC-based replication occurs. 30 An advantage of HBIG as monoprophylaxis may still be seen in patients with renal insufficiency. 40 Adequate prophylaxis might help to control recurrence but should be adjusted to each recipient and especially discontinuation of HBIG can be reevaluated during the long-term run.
| CON CLUS ION
HBV-reinfection is a serious phenomenon and may lead to graft failure and patients' death. Due to the prophylactic use of high genetic barrier to resistance NUCs before and after LT combined with HBIG, HBV-associated transplant hepatitis has become a rare phenome-
non. An uncontrolled HBV-reinfection does not happen anymore. A controlled HBV-reinfection does not lead to fibrosis progression or to a reduced patient survival and the need for HBIG-administration naturally declines.
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